CN106691645A - Vascular drug stent - Google Patents
Vascular drug stent Download PDFInfo
- Publication number
- CN106691645A CN106691645A CN201710064757.0A CN201710064757A CN106691645A CN 106691645 A CN106691645 A CN 106691645A CN 201710064757 A CN201710064757 A CN 201710064757A CN 106691645 A CN106691645 A CN 106691645A
- Authority
- CN
- China
- Prior art keywords
- biodegradable polymer
- medicine
- blood vessel
- medication coat
- active medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 57
- 229940079593 drug Drugs 0.000 title claims abstract description 37
- 230000002792 vascular Effects 0.000 title abstract description 6
- 229920002988 biodegradable polymer Polymers 0.000 claims abstract description 14
- 239000004621 biodegradable polymer Substances 0.000 claims abstract description 14
- 229910052751 metal Inorganic materials 0.000 claims abstract description 7
- 239000002184 metal Substances 0.000 claims abstract description 7
- 210000004204 blood vessel Anatomy 0.000 claims description 22
- 229920001577 copolymer Polymers 0.000 claims description 4
- 229920001519 homopolymer Polymers 0.000 claims description 4
- 229930012538 Paclitaxel Natural products 0.000 claims description 3
- 229920001610 polycaprolactone Polymers 0.000 claims description 3
- FNRMMDCDHWCQTH-UHFFFAOYSA-N 2-chloropyridine;3-chloropyridine;4-chloropyridine Chemical compound ClC1=CC=NC=C1.ClC1=CC=CN=C1.ClC1=CC=CC=N1 FNRMMDCDHWCQTH-UHFFFAOYSA-N 0.000 claims description 2
- 108010041308 Endothelial Growth Factors Proteins 0.000 claims description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 2
- 229920000954 Polyglycolide Polymers 0.000 claims description 2
- DFBIRQPKNDILPW-CIVMWXNOSA-N Triptolide Chemical compound O=C1OCC([C@@H]2C3)=C1CC[C@]2(C)[C@]12O[C@H]1[C@@H]1O[C@]1(C(C)C)[C@@H](O)[C@]21[C@H]3O1 DFBIRQPKNDILPW-CIVMWXNOSA-N 0.000 claims description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 2
- 125000001931 aliphatic group Chemical group 0.000 claims description 2
- 230000001093 anti-cancer Effects 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 claims description 2
- 230000003064 anti-oxidating effect Effects 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims description 2
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 claims description 2
- 229960004588 cilostazol Drugs 0.000 claims description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 2
- 229960003957 dexamethasone Drugs 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 229960002897 heparin Drugs 0.000 claims description 2
- 229920000669 heparin Polymers 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 2
- 239000004632 polycaprolactone Substances 0.000 claims description 2
- 239000004633 polyglycolic acid Substances 0.000 claims description 2
- 239000004626 polylactic acid Substances 0.000 claims description 2
- 150000003180 prostaglandins Chemical class 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- YKUJZZHGTWVWHA-UHFFFAOYSA-N triptolide Natural products COC12CC3OC3(C(C)C)C(O)C14OC4CC5C6=C(CCC25C)C(=O)OC6 YKUJZZHGTWVWHA-UHFFFAOYSA-N 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000011247 coating layer Substances 0.000 claims 1
- 238000007710 freezing Methods 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 claims 1
- 239000011248 coating agent Substances 0.000 abstract description 11
- 238000000576 coating method Methods 0.000 abstract description 11
- 208000007536 Thrombosis Diseases 0.000 abstract description 6
- 208000037803 restenosis Diseases 0.000 abstract 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 3
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 230000001732 thrombotic effect Effects 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- 238000009941 weaving Methods 0.000 description 3
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical class C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000036262 stenosis Effects 0.000 description 2
- 208000037804 stenosis Diseases 0.000 description 2
- 241000165940 Houjia Species 0.000 description 1
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 1
- 229920001244 Poly(D,L-lactide) Polymers 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009954 braiding Methods 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000013034 coating degradation Methods 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 201000006828 endometrial hyperplasia Diseases 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001432 poly(L-lactide) Polymers 0.000 description 1
- YKYONYBAUNKHLG-UHFFFAOYSA-N propyl acetate Chemical class CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 1
- 229920005604 random copolymer Polymers 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 150000004579 taxol derivatives Chemical class 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/02—Inorganic materials
- A61L31/022—Metals or alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/148—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/606—Coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/12—Blood circulatory system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Surgery (AREA)
- Chemical & Material Sciences (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Inorganic Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Cardiology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Materials For Medical Uses (AREA)
Abstract
The invention belongs to the field of medical instruments and particularly relates to a vascular drug stent. The vascular drug stent comprises a braided stent body and a drug coating, the braided stent body is formed by metal wires with shape memory, and the drug coating is formed by biodegradable polymers and active drugs. The design of the braided stent and the degradable coating is combined, so that the purpose of reducing occurrence rate of vascular restenosis and late vascular thrombus is achieved.
Description
Technical field
The invention belongs to medical instruments field, and in particular to a kind of blood vessel drug eluting stent, especially one kind can reduce blood vessel
The Weaving type blood vessel drug eluting stent of ISR, blood vessel advanced thrombus incidence.
Background technology
In recent years, intravascular stent is widely used in treatment coronary artery blood vessel, peripheral blood as a kind of human vas implant
Pipe, intracranial vessel etc..For coronary artery blood vessel, at present frequently with 316L stainless steels, cochrome or platinum evanohm, by sacculus
Dilating catheter is expanded to up to diseased region.And compared with coronary artery, peripheral vascular diameter is relatively bigger, lesion region is also longer, more
Complexity, and be often accompanied by disperse and calcification lesion, supporting role requirement of the support to lesion vesselses is also higher, therefore frequently with from swollen
Support, to reach preferably support and unobstructed blood vessel effect.
For from swollen support, mainly there is cutting support and braided support at present.By application for many years, cutting support can be with
Support stenosis occlusion section blood vessel, reduces blood vessel elasticity and bounces back and moulding again, keeps tube chamber blood flow unobstructed, also narrow again with preventing
Narrow, but also gradually expose some shortcomings simultaneously, such as compliance is not enough, easy fracture, the problems such as thrombotic risk at a specified future date is high.And weave branch
Frame is by the netted body of a silk or multi-filament braiding winding.The braided support of close mesh due to its good compliance, compared with
Strong support force, good adherence quality, excellent fatigue resistance and its blood vessel minor impact is increasingly attracted attention.
The A of Chinese patent literature CN 102114273 disclose a kind of cutting-type Self-expanded stent, with Metal Cutting support sheet
Based on body, cutting-type has deficiency from support is expanded at aspects such as compliance, fracture and thrombotic risks at a specified future date.Chinese patent text
Offer the B of CN 104507510 and disclose a kind of periphery support by shape memory bioresorbable polymers, rack body by
The random copolymer of the rubber-like polymer of PLLA and such as PCL is made, but this macromolecular material rack body
The supporting role of continuous and effective can not be brought, because its degradability may bring the hypodynamic risk of support at a specified future date.In addition, report
The support in road is bare bracket, and surface does not have coated medicament coating.Stent stenosis rate can not effectively be reduced.It is single
The degradable of pure rack body can not bring bigger being benefited.
At present, the coating drug delivery technologies for self expandable braided support are rarely reported.The purpose of the present invention is directed to the above
A kind of technological deficiency, there is provided blood vessel drug eluting stent, it is especially a kind of to reduce reangiostenosis, blood vessel advanced thrombus incidence
Weaving type blood vessel drug eluting stent, i.e., can suppress the coating of degradable medicaments of endometrial hyperplasia in Weaving type stent surface coated, so that
Shortcoming present on the above-mentioned technology of customer service.
The content of the invention
In view of the deficiencies in the prior art, it is an object of the invention to develop a kind of blood vessel drug eluting stent, it can reduce branch
ISR, blood vessel advanced thrombus incidence and reduction thrombosis, improve the validity of product in frame.
The blood vessel drug eluting stent that the present invention is provided, including braided support body and medication coat.
Preferably, described braided support body is selected from one or more metal wire knitted with shape memory and forms.
Preferably, described medication coat is made up of biodegradable polymer and active medicine.
Preferably, described medication coat thickness is 1-20 microns.
Preferably, the percentage by weight of described biodegradable polymer is 5%-95%, the weight of the active medicine
Percentage is 5%-95%, and these percentages are based on the medication coat gross weight.
Preferably, described biodegradable polymer is selected from the homopolymers of aliphatic hydroxyl carboxylic acid or one kind of copolymer
Or it is various.
Preferably, it is described biodegradable polymer, including but not limited to PLA, polyglycolic acid, polycaprolactone, poly-
Homopolymers and its copolymer of acid anhydrides etc..
Preferably, the weight average molecular weight of described biodegradable polymer is 2000-200000 dalton.
Preferably, described active medicine includes anti-oxidation medicine, anticoagulants, anticancer class medicine, suppression blood vessel
Smooth muscle cell proliferation class medicine, one or more promoted in endothelial growth factors, anti-inflammatory drug or immune suppressant drug.
Preferably, described active medicine, including but not limited to rapamycin and its derivative, taxol, Cilostazol,
Match chloropyridine, Triptolide, dexamethasone, prostaglandin, heparin, estrogen, VEGF growth factors, the one of CD34, CD133
Plant or various.
Brief description of the drawings
In order to more clearly describe technical scheme, briefly introduced below in conjunction with accompanying drawing.It is clear that this
A little accompanying drawings are only some specific embodiments that the application is recorded.The present invention includes but is not limited to these accompanying drawings.
Fig. 1 is the planar structure schematic diagram launched vertically of blood vessel drug eluting stent of the embodiment of the present invention.
Fig. 2 is the medication coat schematic diagram in the blood vessel drug eluting stent silk section of the embodiment of the present invention.Wherein 001 is support
Silk, 002 is medication coat.
Specific embodiment
The present invention will be further illustrated by the following examples, but these embodiments are only exemplary, and its purpose exists
In allowing it will be understood by those skilled in the art that the present invention, rather than limiting the scope of the invention.Can also have except exception is implemented
The change of other multi-forms, here without being exhaustive to all of implementation method.Protection scope of the present invention will by right
Book is asked to determine, it is all according to the substantive equivalence changes made of the invention or variation, all it is included within the scope of the present invention.
Embodiment one
Scaffolding thread choice of material niti-shaped memorial alloy, by metal wire knitted into support, structure is as shown in Figure 1.
Take 0.1g poly D, L-lactic acids（PDLLA, weight average molecular weight range is 30000-120000）, it is added at room temperature
10ml n-propyl acetates dissolve, and are configured to uniform solution, are subsequently adding 0.1g rapamycins and are well mixed, the solution that will be configured
Rack surface accurately is sprayed into, vacuum drying chamber drying is placed a stent into, ethane via epoxyethane sterilizing is stand-by, and coating structure state is such as
Shown in Fig. 2.
The poly- D that the present embodiment is used, Pfansteihl will complete drop after the function of completing insoluble drug release in 2 years
Solution.
Embodiment two
Scaffolding thread material is same as Example 1, and by metal wire knitted into support, structure is as shown in Figure 1.
Take 0.1g Poly(D,L-lactide-co-glycolides (poly (lactic-co-glycolic acid)（PLGA, divides equally again
Son amount scope is 20,000-80,000), the dissolving of 10mL tetrahydrofurans is added at room temperature, uniform solution is configured to, then
Add 0.1g taxols to be well mixed, the solution of configuration is accurately sprayed into rack surface, place a stent into vacuum drying chamber baking
Dry, ethane via epoxyethane sterilizing is stand-by, and coating structure state is as shown in Figure 2.
The PLGA that the present embodiment is used will complete degraded after the function of completing insoluble drug release in 9 months.
Embodiment three
Scaffolding thread material is same as Example 1, and by metal wire knitted into support, structure is as shown in Figure 1.
Take 0.1g Poly(D,L-lactide-co-glycolides (poly (lactic-co-glycolic acid)（PLGA, divides equally again
Son amount scope is 3000-20000), the dissolving of 10mL tetrahydrofurans is added at room temperature, it is configured to uniform solution, Ran Houjia
Enter 0.1g rapamycins to be well mixed, the solution of configuration is accurately sprayed into rack surface, place a stent into vacuum drying chamber baking
Dry, ethane via epoxyethane sterilizing is stand-by, and coating structure state is as shown in Figure 2.
The PLGA that the present embodiment is used will complete degraded after the function of completing insoluble drug release in 3 months.
Beneficial effects of the present invention：
The present invention compared with prior art, with advantages below and effect：
Present invention employs self expandable braided support, cutting support compliance deficiency, easy fracture are overcome, thrombotic risk at a specified future date is high
The problems such as, for continuous vessel provides reliable supporting role；
Present invention employs biodegradable coating technology, after medicine completes release, pharmaceutical carrier gradually completes degraded, it is to avoid by
The risk of drug stent late vessel caused by the long-term existence of polymer.
The biodegradable coating technology that the present invention is provided, can be by screening biodegradable polymer, for different lesions
Region, realizes coating degradation from several weeks to the several years, realizes the best match of stent drug release and lesion healing.
The blood vessel drug eluting stent that the present invention is provided, improves the long-term reliability of support, while also solving in support again
The problem of narrow and advanced thrombus.
The explanation of above example is only intended to help and understands core concept of the invention.It should be pointed out that for this area
Those of ordinary skill for, under the premise without departing from the principles of the invention, some improvement can also be carried out to the inventive method
And modification, but these are improved and modification is also fallen into the range of the claims in the present invention are claimed.
Claims (10)
1. a kind of blood vessel drug eluting stent, including braided support body and medication coat.
2. a kind of blood vessel drug eluting stent described in claim 1, wherein described braided support body is selected from has shape memory
One or more metal wire knitted form.
3. a kind of blood vessel drug eluting stent described in claim 1, wherein described medication coat by biodegradable polymer and
Active medicine is constituted.
4. claim 1, the medication coat described in 3, it is characterised in that coating layer thickness is 1-20 microns.
5. claim 1, the medication coat described in 3, it is characterised in that the percentage by weight of described biodegradable polymer
It is 5%-95%, the percentage by weight of the active medicine is 5%-95%, and these percentages are based on the medication coat gross weight.
6. claim 3, the biodegradable polymer described in 5, it is characterised in that described biodegradable polymer is selected from
The homopolymers of aliphatic hydroxyl carboxylic acid or one or more of copolymer.
7. claim 3, the biodegradable polymer described in 5,6, it is characterised in that described biodegradable polymer bag
Include but be not limited to PLA, polyglycolic acid, polycaprolactone, the homopolymers of condensing model and its copolymer etc..
8. claim 3, the biodegradable polymer described in 5,6,7, it is characterised in that weight average molecular weight is 2000-
200000 dalton.
9. claim 3, the active medicine described in 5, it is characterised in that described active medicine includes anti-oxidation medicine, anti-freezing
Blood class medicine, anticancer class medicine, suppress vascular smooth muscle cell curing class medicine, promote endothelial growth factors, anti-inflammatory drug or
One or more in immune suppressant drug.
10. claim 3, the active medicine described in 5,9, it is characterised in that described active medicine, including but not limited to thunder handkerchief
It is mycin and its derivative, taxol, Cilostazol, match chloropyridine, Triptolide, dexamethasone, prostaglandin, heparin, female
Hormone, VEGF growth factors, one or more of CD34, CD133.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710064757.0A CN106691645A (en) | 2017-02-05 | 2017-02-05 | Vascular drug stent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710064757.0A CN106691645A (en) | 2017-02-05 | 2017-02-05 | Vascular drug stent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106691645A true CN106691645A (en) | 2017-05-24 |
Family
ID=58909905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710064757.0A Pending CN106691645A (en) | 2017-02-05 | 2017-02-05 | Vascular drug stent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106691645A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108720971A (en) * | 2018-01-28 | 2018-11-02 | 杭州市第人民医院 | A kind of controllable antibacterial trachea bracket |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5674241A (en) * | 1995-02-22 | 1997-10-07 | Menlo Care, Inc. | Covered expanding mesh stent |
| US5968091A (en) * | 1996-03-26 | 1999-10-19 | Corvita Corp. | Stents and stent grafts having enhanced hoop strength and methods of making the same |
| US6083257A (en) * | 1995-11-01 | 2000-07-04 | Biocompatibles Limited | Braided stent |
| US6165212A (en) * | 1993-10-21 | 2000-12-26 | Corvita Corporation | Expandable supportive endoluminal grafts |
| CN201006050Y (en) * | 2006-10-18 | 2008-01-16 | 北京乐普医疗器械有限公司 | Biodegradable polymer drug-loaded coated cardiovascular stent |
| CN201150578Y (en) * | 2007-12-26 | 2008-11-19 | 上海康德莱企业发展集团有限公司 | Blood vessel weaving stent |
| CN201551421U (en) * | 2009-11-06 | 2010-08-18 | 易生科技(北京)有限公司 | Blood vessel bracket |
| CN102973339A (en) * | 2011-09-05 | 2013-03-20 | 上海市第十人民医院 | Cardia stent with drug coating |
| CN106073957A (en) * | 2016-06-20 | 2016-11-09 | 常州乐奥医疗科技股份有限公司 | A kind of Novel weaved intravascular stent |
-
2017
- 2017-02-05 CN CN201710064757.0A patent/CN106691645A/en active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6165212A (en) * | 1993-10-21 | 2000-12-26 | Corvita Corporation | Expandable supportive endoluminal grafts |
| US5674241A (en) * | 1995-02-22 | 1997-10-07 | Menlo Care, Inc. | Covered expanding mesh stent |
| US6083257A (en) * | 1995-11-01 | 2000-07-04 | Biocompatibles Limited | Braided stent |
| US5968091A (en) * | 1996-03-26 | 1999-10-19 | Corvita Corp. | Stents and stent grafts having enhanced hoop strength and methods of making the same |
| CN201006050Y (en) * | 2006-10-18 | 2008-01-16 | 北京乐普医疗器械有限公司 | Biodegradable polymer drug-loaded coated cardiovascular stent |
| CN201150578Y (en) * | 2007-12-26 | 2008-11-19 | 上海康德莱企业发展集团有限公司 | Blood vessel weaving stent |
| CN201551421U (en) * | 2009-11-06 | 2010-08-18 | 易生科技(北京)有限公司 | Blood vessel bracket |
| CN102973339A (en) * | 2011-09-05 | 2013-03-20 | 上海市第十人民医院 | Cardia stent with drug coating |
| CN106073957A (en) * | 2016-06-20 | 2016-11-09 | 常州乐奥医疗科技股份有限公司 | A kind of Novel weaved intravascular stent |
Non-Patent Citations (5)
| Title |
|---|
| 中国科学技术协会主编: "介入医学工程研究现状与展望", 《生物医学工程学科发展报告》 * |
| 付小兵等: "《创伤基础》", 30 November 2016 * |
| 吕杰等: "生物医用材料性能及其改性", 《生物医用材料导论》 * |
| 方亮主等: "高分子的结构与合成", 《药用高分子材料学》 * |
| 王迎军等: "《新型材料科学与技术 无机材料卷 下》", 31 October 2016 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108720971A (en) * | 2018-01-28 | 2018-11-02 | 杭州市第人民医院 | A kind of controllable antibacterial trachea bracket |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102048602B (en) | Preparation method of meshy degradable blood vessel stent | |
| CN103316382B (en) | Protection-sleeve-carrying paclitaxel drug balloon and preparation method thereof | |
| CN103142335B (en) | A kind of thermoplastic degradable fiber woven stent and preparation method thereof | |
| JP5329435B2 (en) | Coronary stent with asymmetric drug release controlled coating | |
| WO2016173553A1 (en) | Support and drug delivery device | |
| CN107049571A (en) | A kind of vertebral artery stent and preparation method thereof | |
| KR101708748B1 (en) | Spatiotemporal multicontrollable intelligent drug-eluting stent | |
| CN101091806A (en) | Slow release coating layer of degradable medication for bracket of coronary artery | |
| CN104644297A (en) | Bioabsorbable stent and preparation method thereof | |
| CN106618818A (en) | Woven vascular drug stent | |
| CN112263360A (en) | In vivo drug eluting stent and preparation method thereof | |
| JP5102200B2 (en) | In vivo indwelling | |
| CN106691645A (en) | Vascular drug stent | |
| JP2005168937A (en) | Stent | |
| JP5597625B2 (en) | Drug eluting stent | |
| CN202761483U (en) | Biodegradable stent | |
| KR102522542B1 (en) | Drug-eluting stent | |
| JPWO2007116646A1 (en) | In vivo indwelling | |
| CN207721928U (en) | A new type of bioabsorbable drug-loaded stent for femoropopliteal artery | |
| CN116966402A (en) | Medical device for slow release of medicine and preparation method thereof | |
| Lee et al. | Exovascular application of epigallocatechin-3-O-gallate-releasing electrospun poly (L-lactide glycolic acid) fiber sheets to reduce intimal hyperplasia in injured abdominal aorta | |
| CN208892868U (en) | A kind of biodegradable load medicine intravascular stent | |
| CN208552143U (en) | A kind of endovascular stent and product | |
| JP2015154921A (en) | drug sustained-release stent | |
| CN206508085U (en) | A kind of degradable blood vessel open loop support |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170524 |